Indium In-111 pentetate

Identification

Summary

Indium In-111 pentetate放射性药物的诊断代理是用来干嘛的radionuclide cisternography.

Brand Names

Indium DTPA In 111

Generic Name

Indium In-111 pentetate

DrugBank Accession Number

DB09425

Background

Indium In-111 pentetate disodium is a radioactive diagnostic indicated for use in radionuclide cisternography. Decay of In-111 by electron capture allows for detection with a gamma camera for visualization of the brain and spinal column.

Type

Small Molecule

Groups

Approved

Structure

Similar Structures

Weight: Average: 501.23
Monoisotopic: 501.019979533
Chemical Formula: C₁₄H₂₀InN₃O₁₀

Synonyms

Indium (111In) pentetic acid
Indium In 111 pentetate
Indium In-111 pentetate

Pharmacology

Indication

Pentetate Indium Disodium In 111 is recommended for use in radionuclide cisternography.

Reduce drug development failure rates

Build, train, & validate machine-learning models
with evidence-based and structured datasets.

See how

Build, train, & validate predictive machine-learning models with structured datasets.

See how

Contraindications & Blackbox Warnings

Avoid life-threatening adverse drug events

Improve clinical decision support with information oncontraindications & blackbox warnings, population restrictions, harmful risks, & more.

Learn more

Avoid life-threatening adverse drug events & improve clinical decision support.

Learn more

Pharmacodynamics

Not Available

Mechanism of action

Decay of In-111 by electron capture allows for detection with a gamma camera for visualization of the brain and spinal column.

Absorption

After intrathecal administration, the radiopharmaceutical is absorbed from the subarachnoid space as described below, and the remainder flows superiorly to the basal cisterns within 2 to 4 hours and subsequently will be apparent in the Sylvian cisterns, the interhemispheric cisterns, and over the cerebral convexities. In normal individuals, the radiopharmaceutical will have ascended to the parasagittal region within 24 hours with simultaneous partial or complete clearance of activity from the basal cisterns and Sylvian regions. In contrast to air, the radiopharmaceutical does not normally enter the cerebral ventricles. Although the primary absorption of cerebrospinal fluid (CSF) into the blood stream occurs at the arachnoid villi, there is some evidence that a significant fraction of CSF is also absorbed across both the cerebral and spinal leptomeninges. Lesser quantities may also be absorbed across the ventricular ependyma. It is also generally held that these alternate routes of CSF absorption may assume primary importance when the major routes of the flow are pathologically obstructed

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism

Not Available

Route of elimination

Approximately 65% of the administered dose is excreted by the kidneys within 24 hours and this increases to 85% in 72 hours.

Half-life

Indium 111 decays by electron capture with a physical half-life of 67.9 hours.

Clearance

Not Available

Adverse Effects

Improve decision support & research outcomes

With structured adverse effects data, including:blackbox warnings, adverse reactions, warning & precautions, & incidence rates.

Learn more

Improve decision support & research outcomes with our structured adverse effects data.

Learn more

Toxicity

Pregnancy Category C

Aseptic meningitis and pyrogenic reactions have been rarely (less than 0.4%) observed following cisternography

Pathways

Not Available

Pharmacogenomic Effects/ADRsBrowse all" title="" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">

Not Available

Interactions

Drug InteractionsLearn More" title="" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">: This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions: No interactions found.

Products

Drug product information from 10+ global regions

Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.

Access now

Access drug product information from over 10 global regions.

Access now

Product Ingredients

Ingredient	UNII	CAS	InChI Key
Indium In-111 pentetate disodium	7UIT3ZGC8E	60662-14-8	JKGXLBAWNSPIFF-LWQDMHIUSA-I

Active Moieties

Name	Kind	UNII	CAS	InChI Key
Pentetic acid	unknown	7A314HQM0I	67-43-6	QPCDCPDFJACHGM-UHFFFAOYSA-N
Indium cation In-111	ionic	WJZ06C0H8L	131391-70-3	RJMMFJHMVBOLGY-AHCXROLUSA-N

Brand Name Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End	Region	Image
In-111 DTPA	Solution	3.75 mCi/1.5mL	Intrathecal	Anazao Health Corporation	2012-06-19	Not applicable
Indium DTPA In 111	Solution	1 mCi/1mL	Intrathecal	Medi-Physics, Inc. dba GE Healthcare	1982-02-18	Not applicable

Unapproved/Other Products

Name	Ingredients	Dosage	Route	Labeller	Marketing Start	Marketing End	Region	Image
In-111 DTPA	Indium In-111 pentetate disodium(3.75 mCi/1.5mL)	Solution	Intrathecal	Anazao Health Corporation	2012-06-19	Not applicable

Chemical Identifiers

UNII: 5K3UP561AX
CAS number: 135998-32-2
InChI Key: BLALCKLYSDDAOC-JWFOFJTQSA-K
InChI: InChI=1S/C14H23N3O10.In/c18-10(19)5-15(1-3-16(6-11(20)21)7-12(22)23)2-4-17(8-13(24)25)9-14(26)27;/h1-9H2,(H,18,19)(H,20,21)(H,22,23)(H,24,25)(H,26,27);/q;+3/p-3/i;1-4
IUPAC Name: (111In)indium(3+) ion 2-[bis({2-[bis(carboxymethyl)amino]ethyl})amino]acetate
SMILES: [111In+3].OC(=O)CN(CCN(CCN(CC([O-])=O)CC([O-])=O)CC([O-])=O)CC(O)=O

References

一般引用

Not Available

External Links

KEGG Drug: D04527
PubChem Compound: 131704319
PubChem Substance: 347827852
ChemSpider: 25048228
Drugs.com: Drugs.com Drug Page

FDA label

Download (2.04 MB)

Clinical Trials

Clinical TrialsLearn More" title="" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">

Phase	Status	Purpose	Conditions	Count
1	Terminated	Treatment	Brain Neoplasm/Central Nervous System Neoplasm	1

Pharmacoeconomics

Manufacturers

Not Available

Packagers

Not Available

Dosage Forms

Form	Route	Strength
Solution	Intrathecal	3.75 mCi/1.5mL
Solution	Intrathecal	1 mCi/1mL

Prices

Not Available

Patents

Not Available

Properties

State

Not Available

Experimental Properties

Not Available

Predicted Properties

Property	Value	Source
Water Solubility	5.71 mg/mL	ALOGPS
logP	0.11	ALOGPS
logP	-6.3	Chemaxon
logS	-2	ALOGPS
pKa (Strongest Acidic)	1.95	Chemaxon
pKa (Strongest Basic)	8.82	Chemaxon
Physiological Charge	-3	Chemaxon
Hydrogen Acceptor Count	13	Chemaxon
Hydrogen Donor Count	2	Chemaxon
Polar Surface Area	204.71 Å²	Chemaxon
Rotatable Bond Count	16	Chemaxon
Refractivity	118.96 m³·mol^-1	Chemaxon
Polarizability	34.91 Å³	Chemaxon
Number of Rings	0	Chemaxon
Bioavailability	0	Chemaxon
Rule of Five	No	Chemaxon
Ghose Filter	No	Chemaxon
Veber's Rule	No	Chemaxon
医学博士DR-like Rule	No	Chemaxon

Predicted ADMET Features

Not Available

Spectra

Mass Spec (NIST)

Not Available

Spectra

Spectrum	Spectrum Type	Splash Key
Predicted GC-MS Spectrum - GC-MS	Predicted GC-MS	Not Available

Drug created at November 30, 2015 19:10 / Updated at June 12, 2020 17:42

Indium In-111 pentetate

Identification

Structure for Indium In-111 pentetate (DB09425)

Pharmacology

Interactions

Products

Categories

Chemical Identifiers

References

Clinical Trials

Pharmacoeconomics

Properties

Spectra